Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Monnerat, Christian ^a   Le Chevalier, T ^b  

^a Hopital Communal   (Switzerland)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cisplatin free doublet; Gemcitabine; NSCLC; Pemetrexed

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; DOCETAXEL; ETOPOSIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; THYMIDYLATE SYNTHASE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLON CANCER; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG FATALITY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SURVIVAL TIME; VITAMIN SUPPLEMENTATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY;

EID: 33745622428     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj958     Document Type: Review

References (36)

1. Delbaldo C, Michiels S, Syz N et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 2004; 292: 470-484.
2. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
3. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034.
4. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57: 1116-1123.
5. Manegold C. Pemetrexed: Its promise in treating non-small-cell lung cancer. Oncology (Huntingt) 2004; 18: 43-48.
6. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-552.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
8. Adjei AA. Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 2000; 11: 1335-1341.
9. Clarke SJ, Abratt R, Goedhals L et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13: 737-741.
10. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 1194.
11. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
12. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3-10.
13. Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-1826.
14. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1535-1540.
15. Gatzemeier U, Shepherd FA, le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-248.
16. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patents with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
17. Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 12-18.
18. Adjei AA, Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer 2001; 34 Suppl 4: S103-S105.
19. Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118.
20. Tonkinson JL, Worzalla JF, Teng CH et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-3676.
21. Adjei AA, Erlichman C, Sloan JA et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18: 1748-1757.
22. Melemed AS, Larson T, Dudek AZ et al. Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: Second dosing schedule & response. Proc Am Soc Clin Oncol 2005; 23, 684s (abstract 7257).
23. Dy GK, Suri A, Reid JM et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005; 55: 522-530.
24. Monnerat C, Le CT, Kelly K et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004; 10: 5439-5446.
25. Treat J, McCleod M, Mintzer D et al. Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 22, 648s (abstract 7130).
26. Socinski MA, Stinchcombe TE, Hayes DN. The evolving role of pemetrexed (Alimta) in lung cancer. Semin Oncol 2005; 32: S16-S22.
27. Ma CX, Nair S, Thomas S et al. Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2005; 23: 5929-5937.
28. McCleod M, Treat J, Christiansen N et al. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Proc Am Soc Clin Oncol 2005; 23, 650s (abstr 7121).
29. West H, Belt RJ, Wakelee HA et al. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung Gancer (NSCLC): A phase II clinical trial. Proc Am Soc Clin Oncol 2005; 23, 649s (abstr 7117).
30. Bepler G, Sommers KE, Robinson LA et al. Neoadjuvant gemcitabine and pemetrexed (NeoGP) in resectable non-small-cell lung cancer (NSCLC). Lung Cancer 2005; 49 (suppl 2), S39 (abstract 0-111)
31. Clarke SJ, Boyer MJ, Millward M et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005; 49: 401-412.
32. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 2000; 11: 435-440.
33. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92: 595-600.
34. Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11: 690-696.
35. Zinner RG, Kortsik C, Dark GG et al. Pemetrexed plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Phase II results of a multicenter European trial and an MD Anderson Cancer Center (MDACC) trial. Lung Cancer 2005; 49 (Suppl 2), S91 (abstr PD-083).
36. Rosell R, Taron M, Sanchez JM et al. The promise of pharmacogenomics: gemcitabine and pemetrexed. Oncology (Williston.Park) 2004; 18: 70-76.